Study of Anastrozole and Tamoxifen for Breast Cancer
Author Information
Author(s): Trialists' Group The ATAC 1
Primary Institution: UCL Cancer Trials Centre, University College London
Hypothesis
How do anastrozole and tamoxifen alone and in combination affect pharmacokinetics in postmenopausal women with early breast cancer?
Conclusion
The reduction in anastrozole levels by tamoxifen is unlikely to be clinically significant when both drugs are used together.
Supporting Evidence
- The geometric mean anastrozole levels were 27% lower in the presence of tamoxifen than with anastrozole alone.
- The geometric mean steady-state trough plasma concentrations of tamoxifen and DMT were statistically equivalent in both treatment groups.
- On-treatment values for oestradiol were below the detection limit in a significant percentage of patients.
Takeaway
This study looked at how two breast cancer medications work together in women. It found that one medicine doesn't really change how the other works.
Methodology
The study used a randomized, double-blind design and measured plasma concentrations of the drugs in patients who had been compliant with their medication.
Participant Demographics
Postmenopausal women with early breast cancer
Statistical Information
P-Value
< 0.001
Confidence Interval
90% Cl 20–33%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website